(S)-[(9H-Fluoren-9-ylmethoxycarbonylamino)]-naphthalen-1-YL-acetic acid | 1260591-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (S)-[(9H-Fluoren-9-ylmethoxycarbonylamino)]-naphthalen-1-YL-acetic acid
• 英文别名: (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-naphthalen-1-ylacetic acid
• CAS: 1260591-74-9
• 化学式: C₂₇H₂₁NO₄
• 分子量: 423.468
• InChiKey: SCQIIBIYCFZYJE-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 (S)-[(9H-Fluoren-9-ylmethoxycarbonylamino)]-naphthalen-1-YL-acetic acid 、 叔-丁基氯甲酸酯 在 N-甲基吗啉 、 silver trifluoroacetate 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 生成 芴甲氧羰基-(R)-3-氨基-3-(1-萘基)-丙酸
  参考文献：
  名称：

  Immunomodulation with novel pharmaceutical compositions

  摘要：

  提供了一类新型肿瘤坏死因子（TNF&agr;）抑制剂和免疫调节剂的合成和使用。这些化合物具有药理应用，以及在与TNF&agr;和其他相关细胞因子有关的测定中的用途。作为药物，这些化合物被用于治疗与TNF&agr;和/或一个或多个其他相关细胞因子的不需要的存在或活性相关的炎症性、传染性、自身免疫或其他增生性疾病和状况，单独或与其他药物联合使用。本发明的化合物的示例包括具有如下结构的化合物：1其中，a、b和c可以相同也可以不同，是从0到12的整数，X等于NH或CHNH2，R1和R2可以相同也可以不同，等于氢或直链或支链的C1到C20饱和或不饱和脂肪族；脂肪族胺；脂环；单环或多环芳香族；单环或多环芳香杂环；单环或多环饱和杂环及其卤代形式；和2其中，a、b和c可以相同也可以不同，是从0到12的整数；R1、R2、R3和R4可以相同也可以不同，等于氢或直链或支链的C1到C20饱和或不饱和脂肪族；脂肪族胺；脂环；单环或多环芳香族；单环或多环芳香杂环；单环或多环饱和杂环及其卤代形式。

  公开号：

  US20040235960A1

文献信息

• Rational Design of Topographical Helix Mimics as Potent Inhibitors of Protein–Protein Interactions
  作者：Brooke Bullock Lao、Kevin Drew、Danielle A. Guarracino、Thomas F. Brewer、Daniel W. Heindel、Richard Bonneau、Paramjit S. Arora

  DOI：10.1021/ja502310r

  日期：2014.6.4

  Protein-protein interactions encompass large surface areas, but often a handful of key residues dominate the binding energy landscape. Rationally designed small molecule scaffolds that reproduce the relative positioning and disposition of important binding residues, termed "hotspot residues", have been shown to successfully inhibit specific protein complexes. Although this strategy has led to development of novel synthetic inhibitors of protein complexes, often direct mimicry of natural amino acid residues does not lead to potent inhibitors. Experimental screening of focused compound libraries is used to further optimize inhibitors but the number of possible designs that can be efficiently synthesized and experimentally tested in academic settings is limited. We have applied the principles of computational protein design to optimization of nonpeptidic helix mimics as ligands for protein complexes. We describe the development of computational tools to design helix mimetics from canonical and noncanonical residue libraries and their application to two therapeutically important protein-protein interactions: p53-MDM2 and p300-HIF1 alpha. The overall study provides a streamlined approach for discovering potent peptidomimetic inhibitors of protein-protein interactions.
• Immunomodulation with novel pharmaceutical compositions
  申请人：——

  公开号：US20040235960A1

  公开（公告）日：2004-11-25

  The synthesis and use of a novel class of tumor necrosis factor (TNF&agr;) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF&agr; and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF&agr; and/or one or more other involved cytokines, alone or in combination with other agents. Examples of compounds of the present invention are those having the structures as shown below: 1 wherein, a, b and c may be the same or different and are integers from 0 to 12, X equals NH or CHNH 2 , R 1 and R 2 can be the same or different and equal to a hydrogen or a straight or branched C 1 to C 20 saturated or unsaturated aliphatic; aliphatic amine; an alicyclic; single or multi-ring aromatic; a single or multi-ring aromatic heterocycle; a single or multi-ring saturated heterocycle and the halogenated forms thereof; and 2 wherein, a, b and c may be the same or different and are integers from 0 to 12; R 1 , R 2 , R 3 , and R 4 can be the same or different and equal to a hydrogen or a straight or branched C 1 to C 20 saturated or unsaturated aliphatic; aliphatic amine; an alicyclic; single or multi-ring aromatic; a single or multi-ring aromatic heterocycle; a single or multi-ring saturated heterocycle and the halogenated forms thereof.

  提供了一类新型肿瘤坏死因子（TNF&agr;）抑制剂和免疫调节剂的合成和使用。这些化合物具有药理应用，以及在与TNF&agr;和其他相关细胞因子有关的测定中的用途。作为药物，这些化合物被用于治疗与TNF&agr;和/或一个或多个其他相关细胞因子的不需要的存在或活性相关的炎症性、传染性、自身免疫或其他增生性疾病和状况，单独或与其他药物联合使用。本发明的化合物的示例包括具有如下结构的化合物：1其中，a、b和c可以相同也可以不同，是从0到12的整数，X等于NH或CHNH2，R1和R2可以相同也可以不同，等于氢或直链或支链的C1到C20饱和或不饱和脂肪族；脂肪族胺；脂环；单环或多环芳香族；单环或多环芳香杂环；单环或多环饱和杂环及其卤代形式；和2其中，a、b和c可以相同也可以不同，是从0到12的整数；R1、R2、R3和R4可以相同也可以不同，等于氢或直链或支链的C1到C20饱和或不饱和脂肪族；脂肪族胺；脂环；单环或多环芳香族；单环或多环芳香杂环；单环或多环饱和杂环及其卤代形式。